Foudah Ahmed I, Alqarni Mohammed H, Aljarba Tariq M, Jawaid Talha, Alkhamees Osama A, Alsanad Saud M, AlHussaini Khalid I, Alam Aftab
Department of Pharmacognosy, College of Pharmacy, Prince Sattam Bin Abdulaziz University, 11942, Al Kharj, Saudi Arabia.
Department of Pharmacology College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), 13317, Riyadh, Saudi Arabia.
Mol Divers. 2025 Sep 10. doi: 10.1007/s11030-025-11339-8.
Cyclin-dependent kinase 20 (CDK20), also known as cell cycle-related kinase (CCRK), plays a pivotal role in hepatocellular carcinoma (HCC) progression by regulating β-catenin signaling and promoting uncontrolled proliferation. Despite its emerging significance, selective small-molecule inhibitors of CDK20 remain unexplored. In this study, a known CDK20 inhibitor, ISM042-2-048, was employed as a reference to retrieve structurally similar compounds from the PubChem database using an 85% similarity threshold. Out of 6,235 candidates, the top three compounds (153295720, 145037521, and 163292314) were shortlisted through MTiOpenScreen-based virtual screening. Geometry optimizations using density functional theory (B3LYP/cc-pVDZ) refined each ligand's electronic properties before re-docking against the AlphaFold-derived CDK20 structure. 153295720 exhibited the highest binding affinity (- 11.8 kcal/mol), engaging critical active-site residues such as Met, Lys, Ala, and Asp through polar and hydrophobic interactions. Molecular dynamics simulations (500 ns) confirmed the complex's structural stability, with 153295720 showing the lowest RMSD and RMSF fluctuations and highly persistent hydrogen bonding. MM/GBSA analysis further supported its superiority, revealing the most favorable binding energy (- 69.09 ± 8.29 kcal/mol), dominated by van der Waals and electrostatic interactions. Free energy landscape analysis revealed a single dominant basin, and superimposition of MD-derived minima with the docked pose yielded an RMSD of 1.464 Å, supporting pose fidelity. Comparatively, the reference compound displayed greater conformational drift and reduced energetic convergence. This integrative computational approach establishes 153295720 as a structurally and dynamically superior inhibitor, capable of stabilizing key catalytic residues of CDK20. These findings provide a rational basis for the biochemical targeting of CDK20 in HCC and highlight residues essential for selective inhibition, paving the way for experimental validation and lead optimization.
细胞周期蛋白依赖性激酶20(CDK20),也被称为细胞周期相关激酶(CCRK),通过调节β-连环蛋白信号传导并促进不受控制的增殖,在肝细胞癌(HCC)进展中起关键作用。尽管其重要性日益凸显,但CDK20的选择性小分子抑制剂仍未被探索。在本研究中,一种已知的CDK20抑制剂ISM042-2-048被用作参考,以85%的相似性阈值从PubChem数据库中检索结构相似的化合物。在6235个候选化合物中,通过基于MTiOpenScreen的虚拟筛选,选出了排名前三的化合物(153295720、145037521和163292314)。在针对AlphaFold衍生的CDK20结构重新对接之前,使用密度泛函理论(B3LYP/cc-pVDZ)进行几何优化,以改善每个配体的电子性质。153295720表现出最高的结合亲和力(-11.8 kcal/mol),通过极性和疏水相互作用与关键活性位点残基如Met、Lys、Ala和Asp结合。分子动力学模拟(500 ns)证实了复合物的结构稳定性,153295720表现出最低的RMSD和RMSF波动以及高度持久的氢键。MM/GBSA分析进一步支持了它的优势,揭示了最有利的结合能(-69.09±8.29 kcal/mol),主要由范德华力和静电相互作用主导。自由能景观分析揭示了一个单一的主导盆地,将MD衍生的最小值与对接构象叠加产生的RMSD为1.464 Å,支持构象保真度。相比之下,参考化合物表现出更大的构象漂移和降低的能量收敛。这种综合计算方法确定153295720是一种结构和动力学上更优的抑制剂,能够稳定CDK20的关键催化残基。这些发现为HCC中CDK20的生化靶向提供了合理依据,并突出了选择性抑制所必需的残基,为实验验证和先导优化铺平了道路。